Literature DB >> 26057956

Heart failure gene therapy disappoints but experts keep the faith.

Mark Ratner.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26057956     DOI： 10.1038/nbt0615-573a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  First gene therapy nears landmark European market authorization.

Authors:  Nuala Moran
Journal:  Nat Biotechnol       Date:  2012-09       Impact factor: 54.908

2.  Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

Authors:  Brian E Jaski; Mariell L Jessup; Donna M Mancini; Thomas P Cappola; Daniel F Pauly; Barry Greenberg; Kenneth Borow; Howard Dittrich; Krisztina M Zsebo; Roger J Hajjar
Journal:  J Card Fail       Date:  2009-04       Impact factor: 5.712
  2 in total
  3 in total

Review 1.  From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure.

Authors:  Bianca C Bernardo; Burns C Blaxall
Journal:  Heart Lung Circ       Date:  2016-01-19       Impact factor: 2.975

2.  Trigger vs. Substrate: Multi-Dimensional Modulation of QT-Prolongation Associated Arrhythmic Dynamics by a hERG Channel Activator.

Authors:  Michael A Colman; Erick A Perez Alday; Arun V Holden; Alan P Benson
Journal:  Front Physiol       Date:  2017-10-04       Impact factor: 4.566

3.  Overexpression of Sarcoendoplasmic Reticulum Calcium ATPase 2a Promotes Cardiac Sympathetic Neurotransmission via Abnormal Endoplasmic Reticulum and Mitochondria Ca2+ Regulation.

Authors:  Julia Shanks; Neil Herring; Errin Johnson; Kun Liu; Dan Li; David J Paterson
Journal:  Hypertension       Date:  2017-02-21       Impact factor: 10.190
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.